Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
0.6211 ^USD	-1.41%		-8.63%	-13.74%

05-01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
04-29	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

April 29, 2024 at 09:00 pm

Galecto, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 5.48 million compared to USD 12.99 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.51 a year ago.

Diluted loss per share from continuing operations was USD 0.2 compared to USD 0.51 a year ago.

Latest news about Galecto, Inc.

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	05-01	CI
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	12-21	MT
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	12-21	CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23/10/23	CI
HC Wainwright Downgrades Galecto to Neutral From Buy	28/09/23	MT
Galecto Announces Plans to Explore Strategic Alternatives	26/09/23	CI
Galecto to Explore Strategic Options, to Reduce Workforce	26/09/23	MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	26/09/23	CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	26/09/23	CI
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	21/08/23	MT
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	15/08/23	MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon	15/08/23	MT
Top Midday Decliners	15/08/23	MT
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall	15/08/23	MT
Galecto to discontinue development of lung disease treatment	15/08/23	RE
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	15/08/23	CI
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23	CI
Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	20/06/23	MT
Galecto Completes Patient Dosing in Mid-Stage Trial of Lung Disease Drug Candidate	23/05/23	MT
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	17/03/23	MT
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI

Chart Galecto, Inc.

Duration

Period

More charts

Company Profile

Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Companyâs initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Companyâs product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.

Sector

Biotechnology & Medical Research

Calendar

20/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6211 USD

Average target price

6 USD

Spread / Average Target

+866.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GALECTO, INC.	-13.74%	16.84M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs